Sarcoma

Next-Generation Sequencing May Benefit Some Patients With Sarcoma

Next-Generation Sequencing May Benefit Some Patients With Sarcoma

By

Next generation sequencing (NGS) may be highly beneficial in select patients with sarcoma.

Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma

Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma

By

The researchers conducted a retrospective cohort study of patients with advanced STS treated at a single institution over a 12 month period.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Most Utilized Frontline Treatment in Advanced Soft Tissue Sarcoma Across 4 European Countries

Most Utilized Frontline Treatment in Advanced Soft Tissue Sarcoma Across 4 European Countries

By

Approximately 70% of patients were administered anthracyclines as a primary therapy across patient datasets from France, Germany, Spain, and Italy.

Durable Responses Seen With Atezolizumab in Advanced Alveolar Soft Part Sarcoma

Durable Responses Seen With Atezolizumab in Advanced Alveolar Soft Part Sarcoma

By

Durable responses to treatment with atezolizumab in advanced alveolar soft part sarcoma were seen across a phase 2 study.

Crizotinib as the Standard of Care in Advanced IMFT: Researchers Double Down on Proposal

Crizotinib as the Standard of Care in Advanced IMFT: Researchers Double Down on Proposal

By

Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski.

<i>POT1</i> Revealed as a Sarcoma Predisposition Gene

POT1 Revealed as a Sarcoma Predisposition Gene

By

Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.

Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited

Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited

By

Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.

IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up

IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up

By

But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.

Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors

Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors

By

Experts embrace the "less is more" approach to guide treatment decisions in primary sporadic desmoid tumors.

Phase 2 Trial of Abemaciclib in Dedifferentiated Liposarcoma Meets Primary End Point

Phase 2 Trial of Abemaciclib in Dedifferentiated Liposarcoma Meets Primary End Point

By

A subset of patients experienced sustained clinical benefit and at least some objective tumor response.

Dosing Schedule May Be Key to Optimal Administration of Milademetan for Sarcoma Subtype

Dosing Schedule May Be Key to Optimal Administration of Milademetan for Sarcoma Subtype

By

The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.

Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed

Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed

By

Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.

<i>ALK</i> Fusions Thought to Be Oncogenic Drivers in Some Leiomyosarcomas

ALK Fusions Thought to Be Oncogenic Drivers in Some Leiomyosarcomas

By

Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.

Unfavorable Prognosis in Sarcoma May Be Linked to Tumor Involvement of Fascia

Unfavorable Prognosis in Sarcoma May Be Linked to Tumor Involvement of Fascia

By

Patients with fascia-infiltrating sarcoma appeared to have worse survival that those who had either strict superficial or deep soft tissue sarcomas.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Tazemetostat Shows Promise in Epithelioid Sarcoma

Tazemetostat Shows Promise in Epithelioid Sarcoma

By

Epizyme released the results of its phase 2 study of tazemetostat in epithelioid sarcoma.

Triple Angiokinase Inhibitor Shows Preclinical Activity in Synovial Sarcoma

Triple Angiokinase Inhibitor Shows Preclinical Activity in Synovial Sarcoma

By

Results warrant further testing of nintedanib in this disease setting.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma

Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma

By

Cabozantinib demonstrated efficacy in osteosarcoma and Ewing sarcoma in 2 single-arm, phase 2 trials, with objective response rates of 45% and 58%, respectively.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Trial Underway for Checkpoint Blockade in Soft Tissue Sarcoma

Trial Underway for Checkpoint Blockade in Soft Tissue Sarcoma

By

An open-label, single-center, phase 2 trial is underway to evaluate neoadjuvant nivolumab alone and in combination with ipilimumab in soft tissue sarcoma.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Acceptable Safety for Trabectedin Plus Olaparib in Unresectable Sarcoma

Acceptable Safety for Trabectedin Plus Olaparib in Unresectable Sarcoma

By

Trabectedin plus olaparib showed acceptable safety and tolerability in patients with metastatic and unresectable bone and soft-tissue sarcomas.

Single-Agent Ifosfamide in Childhood Sarcoma Not Linked to Long-Term Nephrotoxicity

Single-Agent Ifosfamide in Childhood Sarcoma Not Linked to Long-Term Nephrotoxicity

By

Researchers determined that treatment with ifosfamide in childhood sarcoma did not increase the risk of long-term nephrotoxicity.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

High-Dose Busulfan Plus Melphalan Consolidation Therapy May Improve Outcomes in Ewing Sarcoma

High-Dose Busulfan Plus Melphalan Consolidation Therapy May Improve Outcomes in Ewing Sarcoma

By

Previous studies have suggested that high-dose therapy with busulfan plus melphalan may confer a benefit to patients with Ewing sarcoma compared with conventional chemotherapy.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs